ArticlePharmaceuticals (Basel, Switzerland)2025

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS).

Weidong Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.